Hematologic Toxicity Profile and Efficacy of [225Ac]Ac-PSMA-617 α-Radioligand Therapy of Patients with Extensive Skeletal Metastases of Castration-Resistant Prostate Cancer
Actinium-225-labeled prostate-specific membrane antigen ([225Ac]Ac-PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate cancer (mCRPC). No study has specifically assessed its safety in patients with extensive skeletal metastases of mCRPC. We aimed to investigate the hematologic toxicity and efficacy of [225Ac]Ac-PSMA-617 therapy in patients with extensive skeletal metastases of mCRPC.
LAWAL I;
MORGENSTERN Alfred;
VORSTER Mariza;
KNOESEN Otto;
MAHAPANE Johncy;
HLONGWA Khanyi;
MASERUMULE Letjie;
NDLOVU Honest;
REED Janet;
POPOOLA Gbenga;
MOKOALA K;
MDLOPHANE Amande;
BRUCHERTSEIFER Frank;
SATHEKGE Mike;
2022-07-27
SPRINGER
JRC128874
1619-7070 (online),
https://doi.org/10.1007/s00259-022-05778-w,
https://publications.jrc.ec.europa.eu/repository/handle/JRC128874,
10.1007/s00259-022-05778-w (online),
Additional supporting files
| File name | Description | File type | |
|---|
